The Critical Role of Humanitarian Donations

The Critical Role of Humanitarian Donations

Though humanitarian donations are clearly not the only answer to the complex challenges facing the global oncology community, they do have a critical role to play in reducing inequities in care and extending the lives of certain populations whose local economies and health systems remain years or decades away from facilitating solutions on their own.

In a recent commentary published in the Journal of Global Oncology, co-authors Pat Garcia-Gonzalez MA, Gilberto Lopes MD, Erin Schwartz MSW, and Lawrence Shulman MD, clearly outline the need and efficacy of humanitarian donation programs using lessons learned from the success of joint access initiatives between Novartis and The Max Foundation.

In addition to providing concrete evidence for the need and efficacy of humanitarian donation programs, the paper also demonstrates the terrible human cost that would result from their absence. Garcia-Gonzalez and her co-authors write:

“…in this era of globalization, we are leaving our friends behind and they know it. There is only one thing worse than hearing your loved one is diagnosed with cancer. It is to be told that there is a treatment that could help, but because of the place where you live, your loved one cannot access it and will therefore die a premature and avoidable death.”

Read the full paper here

Read Pat Garcia-Gonzalez’s LinkedIn article

Make a donation to expand treatment access

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    Armenia and Nepal are the first of 29 countries to receive CLL treatment SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and….

  • Targeted Treatment for Advanced Breast Cancer Including CDK4/6 Inhibitor Therapy Reaches Patients in Mozambique for the First Time

    Targeted Treatment for Advanced Breast Cancer Including CDK4/6 Inhibitor Therapy Reaches Patients in Mozambique for the First Time

    Three women diagnosed with HER2- HR+ advanced breast cancer in Mozambique have begun treatment, with efforts underway to open access in eight additional countries  The Max Foundation leading initiative through its Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) with the goal of increasing access to treatment, care, and support at no cost to….

  • The Max Foundation (Max) Expands Board and Global Team to Advance Mission of Accelerating Health Equity

    The Max Foundation (Max) Expands Board and Global Team to Advance Mission of Accelerating Health Equity

    Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….